Lantheus’ (LNTH) Market Outperform Rating Reiterated at Citizens Jmp

Lantheus (NASDAQ:LNTH)‘s stock had its “market outperform” rating reiterated by equities research analysts at Citizens Jmp in a report released on Monday,Benzinga reports. They presently have a $115.00 price target on the medical equipment provider’s stock. Citizens Jmp’s price objective indicates a potential upside of 4.74% from the company’s current price.

Several other analysts also recently weighed in on LNTH. Wall Street Zen downgraded Lantheus from a “strong-buy” rating to a “buy” rating in a research report on Saturday, May 9th. Citigroup reiterated an “outperform” rating on shares of Lantheus in a research report on Friday, May 8th. Truist Financial reissued a “buy” rating and set a $115.00 target price (up from $98.00) on shares of Lantheus in a research note on Monday, May 11th. Jefferies Financial Group reissued a “buy” rating and issued a $110.00 target price on shares of Lantheus in a report on Tuesday, March 17th. Finally, B. Riley Financial restated a “buy” rating on shares of Lantheus in a research note on Friday, May 1st. Eight equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to MarketBeat, Lantheus has a consensus rating of “Moderate Buy” and a consensus price target of $101.86.

Lantheus Price Performance

Shares of LNTH opened at $109.80 on Monday. Lantheus has a one year low of $47.25 and a one year high of $111.46. The company has a market cap of $7.15 billion, a P/E ratio of 26.46 and a beta of -0.03. The company has a debt-to-equity ratio of 0.47, a current ratio of 2.83 and a quick ratio of 2.64. The firm has a 50 day simple moving average of $95.88 and a two-hundred day simple moving average of $80.00.

Lantheus (NASDAQ:LNTH) last released its earnings results on Thursday, May 7th. The medical equipment provider reported $1.46 earnings per share for the quarter, topping the consensus estimate of $1.25 by $0.21. The firm had revenue of $377.33 million during the quarter, compared to analysts’ expectations of $354.48 million. Lantheus had a return on equity of 29.32% and a net margin of 18.05%.The company’s quarterly revenue was up 1.2% on a year-over-year basis. During the same period in the prior year, the company earned $1.53 earnings per share. Lantheus has set its FY 2026 guidance at 5.000-5.250 EPS. Research analysts forecast that Lantheus will post 4.49 EPS for the current fiscal year.

Institutional Trading of Lantheus

A number of hedge funds have recently made changes to their positions in LNTH. Quantbot Technologies LP bought a new stake in Lantheus during the 3rd quarter worth approximately $1,847,000. Heron Bay Capital Management bought a new stake in shares of Lantheus in the third quarter worth $861,000. WINTON GROUP Ltd increased its holdings in Lantheus by 350.8% in the third quarter. WINTON GROUP Ltd now owns 65,125 shares of the medical equipment provider’s stock valued at $3,340,000 after purchasing an additional 50,677 shares during the period. CWA Asset Management Group LLC bought a new position in Lantheus during the 4th quarter worth $1,670,000. Finally, Elo Mutual Pension Insurance Co bought a new position in Lantheus during the 3rd quarter worth $942,000. 99.06% of the stock is owned by institutional investors and hedge funds.

About Lantheus

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.